Table III.
TRIM28 expression | |||||
---|---|---|---|---|---|
Clinicopathological characteristic | Number of patients | High | Low | Pearson's χ2 value | P-value |
Age (years old) | 0.346 | 0.557 | |||
≤50 | 55 | 20 | 35 | ||
>50 | 196 | 63 | 133 | ||
TP53 mutation status | 9.771 | 0.002 | |||
Positive | 58 | 29 | 29 | ||
Negative | 193 | 54 | 139 | ||
ER expression status | 1.954 | 0.162 | |||
Positive | 213 | 68 | 145 | ||
Negative | 34 | 15 | 19 | ||
PR expression status | 5.997 | 0.014 | |||
Positive | 190 | 55 | 135 | ||
Negative | 61 | 28 | 33 | ||
Elston grade | 14.200 | 0.001 | |||
I | 67 | 13 | 54 | ||
II | 128 | 42 | 86 | ||
III | 54 | 28 | 26 | ||
Tumor size (cm) | 2.654 | 0.103 | |||
<2 | 112 | 31 | 81 | ||
≥2 | 139 | 52 | 87 | ||
Lymph node metastasis | 0.410 | 0.522 | |||
Yes | 84 | 30 | 54 | ||
No | 158 | 50 | 108 |
The top 1/3 of patients with the highest TRIM28 expression were defined as the high-expression group and the bottom 2/3 were defined as the low-expression group. P-values were obtained through the Pearson chi-square test for the comparison of the two groups (high vs. low) in different clinicopathological characteristics of patients with BC. ER, estrogen receptor; PR, progesterone receptor; TRIM28, tripartite motif containing 28; TP53, tumor protein p53.